References
- Natural Health Products Regulations. SOR/2003-196. Food and Drug Act. 5 June 2003. Available at: http://laws-lois.justice.gc.ca/eng/regulations/SOR-2003-196/page-1.html [Last accessed 10 January 2015]
- Drugs and Health Products. Health Canada. 21 June 2012. Available at: http://www.hc-sc.gc.ca/dhp-mps/prodnatur/faq/question_general-eng.php [Last accessed 10 January 2015]
- Natural Health Products Directorate – Health Canada. Natural Health Product Tracking Survey – 2010 Final Report. Ipsos-Reid. 13 March 2011. Available at: http://epe.lac-bac.gc.ca/100/200/301/pwgsc-tpsgc/por-ef/health/2011/135-09/report.pdf [Last accessed 10 January 2015]
- Quality of Natural Health Products Guide. 1 May 2015. Available at: http://www.hc-sc.gc.ca/dhp-mps/prodnatur/legislation/docs/eq-paq-eng.php
- Jordan SA, Cunningham DG, Marles RJ. Assessment of herbal medicinal products: challenges, and opportunities to increase the knowledge base for safety assessment. Toxicol Appl Pharmacol 2010;243:198–216
- Barnes J. Pharmacovigilance of herbal medicines: a UK perspective. Drug Saf 2003;26:829–51
- Ankli A, Reich E, Steiner M. Rapid high-performance thin-layer chromatographic method for detection of 5% adulteration of black cohosh with Cimicifuga foetida, C. heracleifolia, C. dahurica, or C. Americana. J AOAC Int 2008;91:1257–64
- Alherbish A, Charrois TL, Ackman ML, et al. The prevalence of natural health product use in patients with acute cardiovascular disease. PloS One 2011;6:e19623
- Morgan TK, Williamson M, Pirotta M, et al. A national census of medicines use: a 24-hour snapshot of Australians aged 50 years and older. Med J Aust 2012;196:50–3
- Necyk C, Tsuyuki RT, Boon H, et al. Pharmacy study of natural health product adverse reactions (SONAR): a cross-sectional study using active surveillance in community pharmacies to detect adverse events associated with natural health products and assess causality. BMJ Open 2014;4:e003431
- Vohra S, Cvijovic K, Boon H, et al. Study of Natural health product Adverse Reactions (SONAR): active surveillance of adverse events following concurrent natural health product and prescription drug use in community pharmacies. PloS One 2012;7:e45196
- Davison KM, Kaplan BJ. Nutrient- and non-nutrient-based natural health product (NHP) use in adults with mood disorders: prevalence, characteristics and potential for exposure to adverse events. BMC Complement Altern Med 2013;13:80
- Fugh-Berman A, Cott JM. Dietary supplements and natural products as psychotherapeutic agents. Psychosomatic Med 1999;61:712–28
- Nahas R, Sheikh O. Complementary and alternative medicine for the treatment of major depressive disorder. Can Fam Physician 2011;57:659–63
- Borrelli F, Izzo AA. Herb–drug interactions with St John’s wort (Hypericum perforatum): an update on clinical observations. AAPS J 2009;11:710–27
- Rogovik AL, Vohra S, Goldman RD. Safety considerations and potential interactions of vitamins: should vitamins be considered drugs? Ann Pharmacother 2010;44:311–24
- Wiktorowicz M.E, Lexchin J, Moscou K, et al. Keeping an eye on prescription drugs, keeping Canadians safe: a commissioned discussion paper. Health Council of Canada 2010. Available at: http://publications.gc.ca/collections/collection_2011/ccs-hcc/H174-21-2010-eng.pdf [Last accessed 10 January 2015]
- Raynor DK, Dickinson R, Knapp P, et al. Buyer beware? Does the information provided with herbal products available over the counter enable safe use? BMC Med 2011;9:94
- Zimmerman M, Grenier D, Levitt M. Does active surveillance of serious and life-threatening adverse drug reactions improve reporting? Paediatr Child Health 2011;16:532–4
- Talabi M, Jeschke E, Bockelbrink A, et al. Educational intervention to improve physician reporting of adverse drug reactions (ADRs) in a primary care setting in complementary and alternative medicine. BMC Public Health 2009;9:274
- StataCorp. 2011. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP.
- I.B.M. Corp. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY, U.S.A.: I.B.M. Corp., 2013
- Medical Dictionary for Regulatory Activities. Available at: http://www.meddra.org [Last accessed 7 March 2016]
- Vasiliadis HM, Tempier R. Reporting on the prevalence of drug and alternative health product use for mental health reasons: results from a national population survey. J Popul Ther Clin Pharmacol 2011;18:e33–43
- Medication Reconciliation. Alberta Health Services. Available at: http://www.albertahealthservices.ca/9322.asp [Last accessed 10 January 2015]
- Rochon PA, Normand S, Gomes T, et al. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med 2008;168:1090–6
- Machado M, Iskedjian M, Ruiz I, et al. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin 2006;22:1825–37
- Dalla Libera D, Colombo B, Pavan G, et al. Complementary and alternative medicine (CAM) use in an Italian cohort of pediatric headache patients: the tip of the iceberg. Neurol Sci 2014;35 (Suppl 1):145–8
- Best Possible Medication History Guidelines for Medication Reconciliation. Ontario College of Pharmacists. March 2007. Available at: http://www.ocpinfo.com/client/ocp/OCPHome.nsf/web/Best+Possible+Medication+History+Guidelines+for+Medication+Reconciliation?OpenDocument&PFV [Last accessed 10 January 2015]
- Medication Reconciliation. Institute for Safe Medication Practices Canada. Available at: http://www.ismp-canada.org/medrec/[Last accessed 10 January 2015]
- Australian Commission on Safety and Quality in Health Care. 2015. Available at: http://www.safetyandquality.gov.au/our-work/medication-safety/medication-reconciliation/[Last accessed 10 January 2015]
- Assuring Medication Accuracy at Transitions in Care. World Health Organization. May 2007. Available at: http://www.who.int/patientsafety/solutions/patientsafety/PS-Solution6.pdf [Last accessed 10 January 2015]
- Giveon SM, Liberman N, Klang S, et al. A survey of primary care physicians’ perceptions of their patients’ use of complementary medicine. Complement Ther Med 2003;11:254–60
- Hiemke C, Pfuhlmann B. Interactions and monitoring of antipsychotic drugs. Handb Exp Pharmacol 2012;212:241–65
- Grohmann R, Engel RR, Möller HJ, et al. Flupentixol use and adverse reactions in comparison with other common first- and second-generation antipsychotics: data from the AMSP study. Eur Arch Psychiatry Clin Neurosci 2014;264:131–41
- Elbe D, Savage R. How does this happen? Part I: mechanisms of adverse drug reactions associated with psychotropic medications. J Can Acad Child Adolesc Psychiatry 2010;19:40–5
- Teferra S, Hanlon C, Beyero T, et al. Perspectives on reasons for non-adherence to medication in persons with schizophrenia in Ethiopia: a qualitative study of patients, caregivers and health workers. BMC Psychiatry 2013;13:168